title: [Stereotactic radiotherapy for lung cancer: Non-invasive real-time tumor tracking].
abstract: OBJECTIVE
  Stereotactic radiation therapy using the CyberKnife(®) has been introduced in France in 2006. Two treatment modalities are currently available: the first one (Synchrony(®)) is a real-time fiducial-based target tracking system, while the other (Xsight Lung Tracking [XLT] System(®)) is completely fiducial-free.
  
  
  METHODS
  Sixty-eight patients were treated for a pulmonary tumor between June 2007 and November 2009. Since august 2008, the XLT System(®) was used for 26 patients. We report the necessary conditions for the XLT System (position, laterality and size of the tumor), the toxicity and outcome of this treatment.
  
  
  RESULTS
  Twenty-two patients were analyzed. Median follow-up was 6 months (min=3; max=16). Local control rate was 100%. The main toxicity was grade grade 1 pulmonary alveolitis (27%). No grade 3 or 4 toxicities were reported.
  
  
  CONCLUSIONS
  The high local control rate and low toxicity obtained with the CyberKnife(®) XLT System(®) suggest that such treatment is an alternative for inoperable patients.
authors.affiliation: Département universitaire de radiothérapie, université Lille II, CyberKnife Nord-Ouest, centre Oscar-Lambret, 3, rue Frédéric-Combemale, BP 307, 59020 Lille cedex, France.
authors.forename: J E
authors.initials: JE
authors.lastname: Bibault
authors.forename: B
authors.initials: B
authors.lastname: Prevost
authors.forename: E
authors.initials: E
authors.lastname: Dansin
authors.forename: X
authors.initials: X
authors.lastname: Mirabel
authors.forename: T
authors.initials: T
authors.lastname: Lacornerie
authors.forename: F
authors.initials: F
authors.lastname: Dubus
authors.forename: E
authors.initials: E
authors.lastname: Lartigau
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D002277:Carcinoma / Q000000981:diagnostic imaging / Q000601:surgery*; D003199:Computer Systems; D019583:Dose Fractionation, Radiation; D005260:Female; D057918:Fiducial Markers / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D007091:Image Processing, Computer-Assisted / Q000295:instrumentation / Q000379:methods*; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D058958:Organs at Risk; D010315:Particle Accelerators / Q000295:instrumentation; D018579:Patient Selection; D019047:Phantoms, Imaging; D017564:Radiation Pneumonitis / Q000209:etiology; D011859:Radiography; D015642:Radiology, Interventional; D016634:Radiosurgery / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D012189:Retrospective Studies; D012371:Robotics; D016896:Treatment Outcome